Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis

Clinica Chimica Acta

Volumn 411, Issue 9-10, 2010, Pages 710-713

  Villalta, Danilo ^a   Morozzi, Gabriella ^b   Tampoia, Marilina ^c   Alpini, Claudia ^d   Brusca, Ignazio ^e   Salgarolo, Valeria ^a   Papisch, Wolfgang ^f   Bizzaro, Nicola ^a  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b Dipartimento di Medicina Clinica e Scienze Immunologiche   (Italy)

^c POLICLINICO   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Buccheri La Ferla Hospital   (Italy)

^f Laboratorio di Patologia Clinica ^*

Author keywords

Anti fibrillarin (AFA) antibodies; Anti PM Scl antibodies; Anti RNA polymerase (anti RNAP) antibodies; Enzyme linked immunosorbent assay (ELISA); Sensitivity; Specificity; Systemic sclerosis (SSc)

Indexed keywords

AUTOANTIBODY; AUTOANTIBODY PM SCL; DNA DIRECTED RNA POLYMERASE III ANTIBODY; FIBRILLARIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; POLYMYOSITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; AUTOANTIGENS; CHROMOSOMAL PROTEINS, NON-HISTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXORIBONUCLEASES; HUMANS; NUCLEAR PROTEINS; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 77950459559     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.01.037     Document Type: Article

References (34)

1. Denton C.P., Black C.M. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004, 18:271-290.
2. Tan E.M., Rodnan G.P., Garcia I., Moroi Y., Fritzler M.J., Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980, 23:617-625.
3. Bryan C., Knight C., Black C.M., Silman A.J. Prediction of five years survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999, 42:2660-2665.
4. Medsger T.A., Silman A.J., Steen V.D., et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999, 26:2159-2167.
5. Steen V.D., Powell D.L., Medsger T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31:196-203.
6. Reveille J.D., Solomon D.H. American College of Rheumatology Ad hoc Committee on Immunological Testing Guidelines. Evidence based guidelines for the use of immunologic tests: anti-centromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 2003, 49:399-412.
7. Spencer-Green G., Alter D., Welch H.G. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med 1997, 103:242-248.
8. Czompoly T., Simon D., Czirjak L., Nemeth P. Anti-topoisomerase I antibodies in systemic sclerosis. Autoimmun Rev 2009, 8:692-696.
9. Bunn C.C., Denton C.P., Shi-Wen X., Knight C., Black C.M. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998, 37:15-20.
10. Koening M., Dieude M., Senecal J.L. Predictive value of antinuclear autoantibodies: the lesson of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593.
11. Reimer G., Steen V.D., Penning C.A., Medsger T.A., Tan E.M. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988, 31:525-532.
12. Tormey V.J., Bunn C.C., Denton C.P., Black C.M. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001, 40:1157-1162.
13. Mahler M., Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007, 6:432-437.
14. Reddy R., Tan E.M., Henning D., Nohga K., Busch H. Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 1983, 258:1383-1386.
15. Tozzoli R., Villalta D. Anti-RNA polymerase III autoantibodies. Autoantibodies 2007, 247-254. Elsevier, Amsterdam. 2nd ed. Y. Shoenfeld, M.E. Gershwin, P.L. Meroni (Eds.).
16. Ho K.T., Reveille J.D. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003, 5:80-93.
17. Kuwana M., Okano Y., Pandey J.P., Silver R.M., Fertig N., Medsger T.A. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005, 52:2425-2432.
18. Mahler M., Fritzler M.J. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?. Autoimmun Rev 2009, 8:373-378.
19. Masi A.T., Rodnan G.P., Medsger T.A., Altman R.D., D'Angelo W.A., Fries J.F. Subcommittee for Scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
20. LeRoy E.C., Black C.M., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
21. Ochs R.L., Lischwe M.A., Spohn W.H., Busch H. Fibrillarin: a new protein of the nucleolus identified by autoimmune sera. Biol Cell 1985, 54:123-133.
22. Wolfe J.F., Adelstein E., Sharp G.C. Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest 1977, 59:176-178.
23. Lischwe M.A., Ochs R.L., Reddy R., et al. Purification and partial characterization of a nucleolar scleroderma antigen (Mr=34, 000, pI=8.5) rich in NG, NG-dimethylarginine. J Biol Chem 1985, 260:14304-14310.
24. Parker J.C., Burlingame R.W., Webb T.T., Bunn C.C. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology (Oxford) 2008, 47:976-979.
25. Kuwana M., Kimura K., Kawakami Y. Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. Arthritis Rheum 2002, 46:2742-2747.
26. Codullo V., Morozzi G., Bardoni A., et al. Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis. Clin Exp Rheum 2007, 27:373-377.
27. Maxwell E.S., Fournier M.J. The small nucleolar RNAs. Annu Rev Biochem 1995, 64:897-934.
28. Santiago M., Baron M., Hudson M., Burlingame R.W., Fritzler M.J. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007, 34:1528-1534.
29. Yamasaki Y., Honkanen-Scott M., Hernandez L., et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 2006, 54:3051-3056.
30. Arnett F.C., Reveille J.D., Goldstein R., et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151-1160.
31. Ruffatti A., Calligaro A., Ferri C., Bombardieri S., Gambari P.F., Todesco S. Association of anti-centromere and anti-Scl 70 antibodies in scleroderma. Report of two cases. J Clin Lab Immunol 1985, 16:227-229.
32. Bizzaro N., Bonelli F., Tonutti E., Villalta D., Tozzoli R. Autoantibody detection in scleroderma patients. Diagnostic and analytical performance of a new coupled particle light scattering immunoassay. Clin Exp Rheumatol 2002, 20:45-51.
33. Cavazzana I., Ceribelli A., Airo P., Zingarelli S., Tincani A., Franceschini F. Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 2009, 8:580-584.
34. van Eenennaam H., Vogelzangs J.H., Bisschops L., et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical association. Clin Exp Immunol 2002, 130:532-540.